NetworkNewsBreaks Archive - Page 2112 of 2180

WednesdayMar 22, 2017 12:29 pm

NetworkNewsBreaks – United Health Products, Inc. (UEEC) Covered at SeeThruEquity

SeeThruEquity has issued a preliminary coverage report on United Health Products (OTCQB: UEEC). The report follows the company’s recently filed application with the FDA to expand use indications for its lead product candidate, Hemostyp®, an all-natural hemostatic agent that has demonstrated the ability to quickly control bleeding from open wounds and body cavities. Hemostyp® Topical Hemostatic Dressing is FDA approved as a Class 1 device and is sold in prescription and over-the-counter forms. If approved by the FDA, the indications for Hemostyp® would be expanded to include use in general surgery, opening a new form of revenue for the company.…

WednesdayMar 22, 2017 12:27 pm

NetworkNewsBreaks – MGX Minerals (MGXMF) Takes Aim at Growing Lithium Market With Cheaper Extraction Process

MGX Minerals (OTC: MGXMF) holds the largest lithium portfolio in Canada and has its sights set on the booming global lithium market, projected to reach $5.87 billion by 2020. “Positive developments have made the company’s lithium operations a special point of interest. An important factor is the company’s engineering partner Purlucid Treatment Solutions, which has developed technologies representing a major step in the process of extracting lithium from petroleum brine water (petrolithium). MGX already holds the largest lithium portfolio in Canada, with its Sturgeon Lake property in Alberta and other lithium assets, and the company is the sole proprietary technology…

WednesdayMar 22, 2017 12:24 pm

NetworkNewsBreaks – National Waste Management Holdings, Inc. (NWMH) Maintains Steady Focus on Expansion

National Waste Management Holdings (OTC: NWMH) has set what some would consider a lofty objective of four acquisitions per year. With an impressive track record of doing so, however, the management team at National Waste has demonstrated its ability to meet this goal and diversify its revenue streams. “These days, National Waste continues to press forward with an aggressive business model that calls for one acquisition per quarter by seeking out acquisitive opportunities in Upstate New York and Florida. To name a few, the company acquired both Sivart Services, a roll-off and compactor company in Worchester, NY, and Northeast Data…

WednesdayMar 22, 2017 12:22 pm

NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Shares Spike on Orphan Drug Designation for Annamycin

Moleculin Biotech (NASDAQ: MBRX) shares are 31% higher mid-morning after the company said it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for Annamycin for the treatment of acute myeloid leukemia (AML). This designation will provide the company several benefits, such as tax credits for qualified clinical trials costs, exemptions from certain FDA application fees, and seven years of market exclusivity upon regulatory product approval. "We are pleased to report this key milestone and the FDA's decision to grant Annamycin orphan drug designation. We look forward to announcing additional milestones in regard to our clinical…

WednesdayMar 22, 2017 11:18 am

NetworkNewsBreaks – TapImmune, Inc. (NASDAQ: TPIV) Announces Participation in Two Upcoming Investor and Industry Conferences

Clinical-stage immuno-oncology company TapImmune, Inc. (NASDAQ: TPIV) today announced plans to participate in two upcoming investor and industry conferences. First, Dr. Glynn Wilson, chairman and CEO of TapImmune, will be offering an overview of the company’s business, clinical pipeline and partnering opportunities for its proprietary PolyStart technology platform at the 5th Annual Cancer Biopartnering & Investment Forum hosted by Sachs Associates in New York City. Wilson’s presentation is scheduled for 10:35 am ET on Tuesday, March 28, 2017. The full presentation will be webcast live and archived for future viewing at http://tapimmune.com/events. Second, Dr. John Bonfiglio, president and chief operating…

WednesdayMar 22, 2017 10:44 am

NetworkNewsBreaks – UniPixel, Inc. (NASDAQ: UNXL) Defies Market Slump; Shares Rise on Multi-Year Deal with Major PC Maker

Shares of UniPixel (NASDAQ: UNXL) are up more than 16% this morning after the company said it has entered into a long-term agreement with a major U.S.-based PC maker to supply XTouch touch screen sensors for multiple years. Per the agreement, the PC maker will supply rolling forecasts to UniPixel and will use its best commercial efforts to make the purchases outlined in the rolling forecasts. The company will reserve manufacturing capacity for the PC maker based off of the rolling forecasts. The agreement also permits the PC maker to request limited, exclusive early access to certain technology development advancements,…

TuesdayMar 21, 2017 1:24 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on March 21, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: PULM 25.90% – News: Receives key patent from European Union HTBX 9.68% – News: Releases latest results from phase 2 trial of HS-110 in combination with nivolumab SPYR 9.09% – News: Issues shareholder update SPDL 7.76% – News: Enters digital marketing partnership with Mach One Media Group CATS 6.84% – News: Expands its OnTrak™-C coverage to Texas with leading insurance provider LOTE 5.97% – News: Appoints new CEO, plans first acquisition OWCP 5.38% –…

TuesdayMar 21, 2017 1:10 pm

NetworkNewsBreaks – Cellectar Biosciences, Inc. (NASDAQ: CLRB) Obtains Patent for Use of CLR 124 in PET Imaging

Cellectar Biosciences (NASDAQ: CLRB) this morning said the United States Patent and Trademark Office has granted a method of use patent for CLR 124, the cancer imaging agent that utilizes the company’s proprietary phospholipid drug conjugate (PDC) delivery platform. The newly issued patent, titled “Phospholipid Ether Analogs as Agents for Detecting and Locating Cancer and Methods Thereof,” provides intellectual property protection through March 2, 2025. The patent outlines the use of CLR 124 in PET imaging to detect radiation-insensitive or chemotherapy-insensitive cancers and cancer metastases. Additionally, the patent provides coverage for the use of CLR 124 in identifying the location…

TuesdayMar 21, 2017 1:04 pm

NetworkNewsBreaks – Celldex Therapeutics, Inc. (NASDAQ: CLDX) Reiterated with “Buy” Rating, $10 PT at Aegis Capital

Aegis Capital has reiterated a ‘Buy’ rating and price target of $10 on shares of Celldex Therapeutics’ (NASDAQ: CLDX) stock. The news follows the company’s report of business and financial highlights for the fourth quarter and year-ended December 31, 2016. The company reported total revenue of $1.9 million in the fourth quarter of 2016, and full-year revenue of $6.8 million, compared to $1.8 million and $5.5 million for the comparable periods in 2015. The company credited the increase in revenue to its clinical trial collaboration with Bristol-Myers Squibb. The company also provided an update on its pipeline, including the increase…

TuesdayMar 21, 2017 12:53 pm

NetworkNewsBreaks – Caladrius Biosciences, Inc. (NASDAQ: CLBS) Receives “Buy” Rating, $15 PT at Aegis Capital

Aegis Capital has issued a ‘Buy’ rating and price target of $15 on shares of Caladrius Biosciences’ (NASDAQ: CLBS) stock. The company recently reported financial results for the three and 12 months ended December 31, 2016. The company full year revenues of $35.3 million, an increase of 57% compared with $22.5 million for 2015. Caladrius also reported cash at year-end of $14.7 million. Additionally, the company recently announced the sale of the remaining 80.1% interest in its PCT LLC subsidiary to Hitachi Chemical for $75 million in cash with an additional $5 million payable upon reaching an undisclosed revenue milestone…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks